Status:
RECRUITING
Mutational Oncology in Clinical Practice
Lead Sponsor:
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Conditions:
Genome Instability
Genetic Predisposition to Disease
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The study of biological profiling is of fundamental importance in the diagnosis and treatment of many diseases, particularly oncological ones, and for this reason, the integration of molecular charact...
Eligibility Criteria
Inclusion
- \- Patients with neoplasm of the lung, breast, ovary, pancreas, prostate, colorectum, melanoma, GIST, thyroid neoplasm, endometrium, and cholangiocarcinoma:
- BREAST Locally advanced or metastatic, hormone-responsive, HER2-negative breast neoplasm, progressing after endocrine therapy.
- LUNG Metastatic disease.
- OVARY Any stage of nonmucinous, non-borderline epithelial carcinoma of the ovary, fallopian tube, or primary peritoneal carcinoma.
- PANCREAS Metastatic disease.
- PROSTATE Metastatic castration-resistant disease.
- COLORECTUM Metastatic disease.
- MELANOMA Stage IV or stage III undergoing surgery.
- GIST Profiling of c-KIT in case of metastatic disease or for patients undergoing surgery and of PDGFRα for all patients with inoperable or metastatic disease.
- THYROID
- ENDOMETRIUM
- CHOLANGIOCARCINOMA
Exclusion
Key Trial Info
Start Date :
January 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2032
Estimated Enrollment :
20000 Patients enrolled
Trial Details
Trial ID
NCT06020625
Start Date
January 1 2022
End Date
January 1 2032
Last Update
August 31 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Rome, Italy